ylmethoxy]-pyridin-3-yl}-methanone;
{6-[3-(4-Chloro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-pyridin-3-yl}-morpholin-4-yl-methanone;
[6-(5-Methyl-3-pyridin-2-yl-isoxazol-4-ylmethoxy)-pyridin-3-yl]-morpholin-4-yl-methanone;
6-[3-(5-Fluoro-pyridin-2-yl)-5-methyl-isoxazol-4-ylmethoxy]-isopropyl-nicotinamide;
(1,1-Dioxo-1,6-thiomorpholin-4-yl)-{6-[3-(5-fluoro-pyridin-2-yl)-5-methyl-isoxazol-4-ylmethoxy]-pyridin-3-yl}-methanone;
{6-[3-(5-Chloro-pyridin-2-yl)-5-methyl-isoxazol-4-ylmethoxy]-pyridin-3-yl}-thiomorpholin-4-yl-methanone; or a pharmaceutically acceptable salt thereof.

61. A GABA A α5 negative allosteric modulator according to any of claims 45 to 54, or 58 to 60, wherein said GABA A α5 negative allosteric modulator is (1,1-Dioxo-1,6-thiomorpholin-4-yl)-{6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-pyridin-3-yl}-methanone or a pharmaceutically acceptable salt thereof.

62. A GABA A α5 negative allosteric modulator according to any of claims 45 to 61, wherein said GABA A α5 negative allosteric modulator is used separately, sequentially or simultaneously in combination with a second active pharmaceutical compound.

~~63. The invention as described hereinbefore.~~

***